- the pharmaceutical formulation, which is able to mask the unpleasant taste of sodium phenylbutyrate - the clinical follow-up data of 17 patients treated with PHEBURANE under the terms of a temporary usage authorisation (TUA), who showed fewer episodes of vomiting and hyperammonaemic decompensation on PHEBURANE by comparison with AMMONAPS,
PHEBURANE offers a minor improvement in actual benefit (IAB IV) over AMMONAPS as adjunctive therapy in the long-term management of urea cycle disorders involving deficiency in carbamoyl phosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.
Listen
